METHODS: Retrospective cohort study of 79 patients 79 eyes in different types of RVO(BRVO:54; non-ischemic CRVO: 16; ischemic CRVO: 9)received intravitreal injection of conbercept. After 3mo injection of conbercept(IVIC), a pro re nata(PRN)strategy was adopted. The best-corrected visual acuity(BCVA,LogMAR)and central macular thickness(CMT)were recorded at baseline and at 1d, 1, 2, 3, 4, 5, 6mo post-treatment.

RESULTS: At 6mo, in different types of RVO, the BCVA were improved significantly than baseline(0.22±0.23 vs 0.70±0.32; 0.24±0.19 vs 0.73±0.27; 1.20±0.37 vs 1.92±0.23; all P<0.05). CMT were decreased significantly than baseline(199±27 vs 422±162μm; 195±16 vs 550±158μm; 231±55 vs 583±152μm; all P<0.05). In three different treatment time groups, CMT in different types of RVO were decresed than the baselineat different time points after treatment(P<0.05), and there was no difference between groups(P>0.05). In three different treatment time groups, BCVA in BRVO and non-iCRVO were improved than the baseline in three groups(P<0.05), but in iCRVO there were little improved in >90d group.

CONCLUSION: Intravitreal injection of conbercept can effectively treat macular edema caused by RVO. Early and timely treatment of anti-VEGF may help improve and maintain the stability of long-term vision, and delayed anti-VEGF treatment may reduce the space for the improving vision.